

## BCL-2(Ab-70) Antibody

Catalog No: #21060

Package Size: #21060-1 50ul #21060-2 100ul

Orders: order@signalwayantibody.com

Support: tech@signalwayantibody.com

## Description

Product Name	BCL-2(Ab-70) Antibody
Host Species	Rabbit
Clonality	Polyclonal
Purification	Antibodies were produced by immunizing rabbits with synthetic peptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific peptide.
Applications	WB IHC IF
Species Reactivity	Hu
Specificity	The antibody detects endogenous level of total BCL-2 protein.
Immunogen Type	Peptide-KLH
Immunogen Description	Peptide sequence around aa.68~72 (R-T-S-P-L) derived from Human BCL-2.
Target Name	BCL-2
Other Names	BCL2
Accession No.	Swiss-Prot: P10415NCBI Protein: NP_000624.2
Uniprot	P10415
GeneID	596;
Concentration	1.0mg/ml
Formulation	Supplied at 1.0mg/mL in phosphate buffered saline (without Mg <sup>2+</sup> and Ca <sup>2+</sup> ), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Storage	Store at -20°C for long term preservation (recommended). Store at 4°C for short term use.

## Application Details


Predicted MW: 26kd

Western blotting: 1:500~1:1000


Immunohistochemistry: 1:50~1:100

Immunofluorescence: 1:100~1:200


## Images



Western blot analysis of extracts from MCF cells using BCL-2(Ab-70) Antibody #21060 and the same antibody preincubated with blocking peptide.



Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using BCL-2(Ab-70) Antibody #21060(left) or the same antibody preincubated with blocking peptide(right).



Immunofluorescence staining of methanol-fixed HeLa cells using BCL-2(Ab-70) Antibody #21060.

## Background

BCL-2 encodes an integral outer mitochondrial membrane protein that blocks the apoptotic death of some cells such as lymphocytes. Constitutive expression of BCL2, such as in the case of translocation of BCL2 to Ig heavy chain locus, is thought to be the cause of follicular lymphoma. Two transcript variants, produced by alternate splicing, differ in their C-terminal ends.

Muller IM, et al. (2005) Mol Pharmacol.

Jin Z, Gao F, et al. J Biol Chem 2004 Sep 17; 279(38): 40209-19.

Kumar Biswas S, et al. Mol Cancer Ther 2004 Mar; 3(3): 327-34.

Huang ST, et al. (2002)FASEB J; 16(8): 825-32.

Yamamoto K, et al. (1999) Mol Cell Biol; 19(12): 8469-78.

Note: This product is for in vitro research use only